good news
recently, salubris announced that the new anti-hypertension drug “allisartan and amlodipine tablets” (folitan®) had obtained the drug registration certificate issued by nmpa.
allisartan and amlodipine tablets (folitan®), a domestic original arb/ccb compound preparation(project code: sal0107), is used for the treatment of essential hypertension, indicated for adult patients with poor blood pressure control treated with allisartan isoproxil alone or amlodipine alone.
allisartan and amlodipine tablets (folitan®) have classic components, high reliability, and well-proven antihypertensive efficacy. after the launch of the product, it will be targeting hypertension patients in varied segments, and form strategic synergy with salubris’ listed class 1 innovative drug xinlitan (allisartan isoproxil tablets) in multiple channels, enriching the innovative product pipeline in the field of hypertension, and enhance salubris’ comprehensive competitiveness in the field of chronic disease.
| general information of drug registration certificate
· generic name: allisartan and amlodipine tablets
· dosage forms: tablet
· strengths: allisartan isoproxil 240mg and amlodipine besylate (as measured by amlodipine) 5mg tablets
· registration classification: chemical 2.3
· drug approval number: 国药准字h20240016